RÉSUMÉ
Limited observation sites and insufficient monitoring of atmospheric CO2 in urban areas restrict our comprehension of urban-suburban disparities. This research endeavored to shed light on the urban-suburban differences of atmospheric CO2 in levels, diurnal and seasonal variations as well as the potential sources and impact factors in the megacity of Hangzhou, China, where the economically most developed region in China is. The observations derived from the existing Hangzhou Atmospheric Composition Monitoring Center Station (HZ) and Lin'an Regional Atmospheric Background Station (LAN) and the newly established high-altitude Daming Mountain Atmospheric Observation Station (DMS), were utilized. From November 2020 to October 2021, the annual averages of HZ, LAN and DMS were 446.52 ± 17.01 ppm, 441.56 ± 15.42 ppm, and 422.02 ± 10.67 ppm. The difference in atmospheric CO2 mole fraction between HZ and LAN was lower compared to the urban-suburban differences observed in other major cities in China, such as Shanghai, Nanjing, and Beijing. Simultaneous CO2 enhancements were observed at HZ and LAN, when using DMS observations as background references. The seasonal variations of CO2 at LAN and DMS exhibited a high negative correlation with the normalized difference vegetation index (NDVI) values, indicating the strong regulatory of vegetation canopy. The variations in boundary layer height had a larger influence on the low-altitude HZ and LAN stations than DMS. Compared to HZ and LAN, the atmospheric CO2 at DMS was influenced by emissions and transmissions over a wider range. The potential source area of DMS in autumn covered most areas of the urban agglomeration in eastern China. DMS measurements could provide a reliable representation of the background level of CO2 emissions in the Yangtze River Delta and a broader region. Conventional understanding of regional CO2 level in the Yangtze River Delta through LAN measurements may overestimate background concentration by approximately 10.92 ppm.
RÉSUMÉ
Antimicrobial resistance has made a sizeable impact on public health and continues to threaten the effectiveness of antibacterial therapies. Novel bacterial topoisomerase inhibitors (NBTIs) are a promising class of antibacterial agents with a unique binding mode and distinct pharmacology that enables them to evade existing resistance mechanisms. The clinical development of NBTIs has been plagued by several issues, including cardiovascular safety. Herein, we report a sub-series of tricyclic NBTIs bearing an amide linkage that displays promising antibacterial activity, potent dual-target inhibition of DNA gyrase and topoisomerase IV (TopoIV), as well as improved cardiovascular safety and metabolic profiles. These amide NBTIs induced both single- and double-strand breaks in pBR322 DNA mediated by Staphylococcus aureus DNA gyrase, in contrast to prototypical NBTIs that cause only single-strand breaks. Unexpectedly, amides 1a and 1b targeted human topoisomerase IIα (TOP2α) causing both single- and double-strand breaks in pBR322 DNA, and induced DNA strand breaks in intact human leukemia K562 cells. In addition, anticancer drug-resistant K/VP.5 cells containing decreased levels of TOP2α were cross-resistant to amides 1a and 1b. Together, these results demonstrate broad spectrum antibacterial properties of selected tricyclic NBTIs, desirable safety profiles, an unusual ability to induce DNA double-stranded breaks, and activity against human TOP2α. Future work will be directed toward optimization and development of tricyclic NBTIs with potent and selective activity against bacteria. Finally, the current results may provide an additional avenue for development of selective anticancer agents.
Sujet(s)
DNA gyrase , Inhibiteurs des topoisomérases , Humains , Inhibiteurs des topoisomérases/pharmacologie , DNA gyrase/métabolisme , DNA topoisomerase IV , Antibactériens/pharmacologie , Antibactériens/composition chimique , Staphylococcus aureus/métabolisme , ADN , Amides/pharmacologie , Inhibiteurs de la topoisomérase-II/pharmacologie , Tests de sensibilité microbienneRÉSUMÉ
Novel bacterial topoisomerase inhibitors (NBTIs) are an emerging class of antibacterials that target gyrase and topoisomerase IV. A hallmark of NBTIs is their ability to induce gyrase/topoisomerase IV-mediated single-stranded DNA breaks and suppress the generation of double-stranded breaks. However, a previous study reported that some dioxane-linked amide NBTIs induced double-stranded DNA breaks mediated by Staphylococcus aureus gyrase. To further explore the ability of this NBTI subclass to increase double-stranded DNA breaks, we examined the effects of OSUAB-185 on DNA cleavage mediated by Neisseria gonorrhoeae gyrase and topoisomerase IV. OSUAB-185 induced single-stranded and suppressed double-stranded DNA breaks mediated by N. gonorrhoeae gyrase. However, the compound stabilized both single- and double-stranded DNA breaks mediated by topoisomerase IV. The induction of double-stranded breaks does not appear to correlate with the binding of a second OSUAB-185 molecule and extends to fluoroquinolone-resistant N. gonorrhoeae topoisomerase IV, as well as type II enzymes from other bacteria and humans. The double-stranded DNA cleavage activity of OSUAB-185 and other dioxane-linked NBTIs represents a paradigm shift in a hallmark characteristic of NBTIs and suggests that some members of this subclass may have alternative binding motifs in the cleavage complex.
Sujet(s)
DNA topoisomerase IV , Neisseria gonorrhoeae , Humains , DNA gyrase/métabolisme , Cassures double-brin de l'ADN , Inhibiteurs de la topoisomérase-II/pharmacologie , Inhibiteurs de la topoisomérase-II/composition chimiqueRÉSUMÉ
Multidrug-resistant bacteria infect companion animals and livestock in addition to their devastating impact on human health. Novel Bacterial Topoisomerase Inhibitors (NBTIs) with excellent activity against Gram-positive bacteria have previously been identified as promising new antibacterial agents. Herein, we evaluate the antibacterial activity of these NBTIs against a variety of important veterinary pathogens and demonstrate outstanding in vitro activity, especially against staphylococci.
Sujet(s)
Bactéries , Inhibiteurs des topoisomérases , Animaux , Humains , Inhibiteurs des topoisomérases/pharmacologie , Relation structure-activité , Antibactériens/pharmacologie , Bactéries à Gram positif , Tests de sensibilité microbienne/médecine vétérinaireRÉSUMÉ
The development of novel treatments for Staphylococcus aureus infections remains a high priority worldwide. We previously reported compounds 0147 and 0186, novel bacterial topoisomerase inhibitors (NBTIs) with potent antibacterial activity against S. aureus, including methicillin-resistant S. aureus. Here, we further investigated the in vitro activity of 0147 and 0186 against S. aureus ATCC 29213. Both compounds demonstrated bactericidal activity against planktonic and biofilm S. aureus, which then translated into significant inhibition of biofilm formation. Combinations of NBTIs and glycopeptides yielded indifferent interactions against planktonic S. aureus, but several had synergistic effects against S. aureus biofilms. This work reinforces the potential of NBTIs as future therapeutics for S. aureus infections. IMPORTANCE The pathogen Staphylococcus aureus contributes substantially to infection-related mortality. Biofilms render bacteria more recalcitrant to antibacterial therapy. The manuscript describes the potent activity of a new class of antibacterial agents against both planktonic and biofilm populations of Staphylococcus aureus.
Sujet(s)
Staphylococcus aureus résistant à la méticilline , Infections à staphylocoques , Humains , Staphylococcus aureus , Inhibiteurs des topoisomérases/pharmacologie , Tests de sensibilité microbienne , Antibactériens/pharmacologie , Antibactériens/composition chimique , Infections à staphylocoques/traitement médicamenteux , Infections à staphylocoques/microbiologie , Biofilms , Dioxanes/pharmacologieRÉSUMÉ
Antibacterial resistance continues its devastation of available therapies. Novel bacterial topoisomerase inhibitors (NBTIs) offer one solution to this critical issue. Two series of amine NBTIs bearing tricyclic DNA-binding moieties as well as amide NBTIs with a bicyclic DNA-binding moiety were synthesized and evaluated against methicillin-resistant Staphylococcus aureus (MRSA). Additionally, these compounds and a series of bicyclic amine analogues displayed high activity against susceptible and drug-resistant Neisseria gonorrhoeae, expanding the spectrum of these dioxane-linked NBTIs.
RÉSUMÉ
Novel bacterial topoisomerase inhibitors (NBTIs) are among the most promising new antibiotics in preclinical/clinical development. We previously reported dioxane-linked NBTIs with potent antistaphylococcal activity and reduced hERG inhibition, a key safety liability. Herein, polarity-focused optimization enabled the delineation of clear structure-property relationships for both microsomal metabolic stability and hERG inhibition, resulting in the identification of lead compound 79. This molecule demonstrates potent antibacterial activity against diverse Gram-positive pathogens, inhibition of both DNA gyrase and topoisomerase IV, a low frequency of resistance, a favorable in vitro cardiovascular safety profile, and in vivo efficacy in a murine model of methicillin-resistant Staphylococcus aureus infection.
Sujet(s)
Antibactériens/pharmacologie , Dioxanes/pharmacologie , Antienzymes/pharmacologie , Canaux potassiques éther-à-go-go/antagonistes et inhibiteurs , Staphylococcus aureus résistant à la méticilline/effets des médicaments et des substances chimiques , Antibactériens/synthèse chimique , Antibactériens/composition chimique , DNA gyrase/métabolisme , DNA topoisomerase IV/antagonistes et inhibiteurs , DNA topoisomerase IV/métabolisme , Dioxanes/synthèse chimique , Dioxanes/composition chimique , Relation dose-effet des médicaments , Antienzymes/synthèse chimique , Antienzymes/composition chimique , Canaux potassiques éther-à-go-go/métabolisme , Humains , Tests de sensibilité microbienne , Structure moléculaire , Relation structure-activitéRÉSUMÉ
In recent years, novel bacterial topoisomerase inhibitors (NBTIs) have been developed as future antibacterials for treating multidrug-resistant bacterial infections. A series of dioxane-linked NBTIs with an amide moiety has been synthesized and evaluated. Compound 3 inhibits DNA gyrase, induces the formation of single strand breaks to bacterial DNA, and achieves potent antibacterial activity against a variety of Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Optimization of this series of analogues led to the discovery of a subseries of compounds (22-25) with more potent anti-MRSA activity, dual inhibition of DNA gyrase and topoisomerase IV, and the ability to induce double strand breaks through inhibition of S. aureus DNA gyrase.
RÉSUMÉ
A series of Novel Bacterial Topoisomerase Inhibitors (NBTIs) employing a linker derived from isomannide were synthesized and evaluated. Reduced hERG inhibition was observed compared to structure-matched analogues with different linkers, and compound 6 showed minimal proarrhythmic potential using an in vitro panel of cardiac ion channels. Compound 6 also displayed excellent activity against fluoroquinolone-resistant MRSA (MIC90 = 2 µg/mL) and other Gram-positive pathogens.
Sujet(s)
Antibactériens/pharmacologie , Composés hétérocycliques bicycliques/pharmacologie , Bactéries à Gram positif/effets des médicaments et des substances chimiques , Inhibiteurs des topoisomérases/pharmacologie , Antibactériens/synthèse chimique , Antibactériens/composition chimique , Composés hétérocycliques bicycliques/synthèse chimique , Composés hétérocycliques bicycliques/composition chimique , Relation dose-effet des médicaments , Tests de sensibilité microbienne , Structure moléculaire , Relation structure-activité , Inhibiteurs des topoisomérases/synthèse chimique , Inhibiteurs des topoisomérases/composition chimiqueRÉSUMÉ
Nicotinamide adenine dinucleotide (NAD+)-dependent ADP-ribosylation plays important roles in physiology and pathophysiology. It has been challenging to study this key type of enzymatic post-translational modification in particular for protein poly-ADP-ribosylation (PARylation). Here we explore chemical and chemoenzymatic synthesis of NAD+ analogues with ribose functionalized by terminal alkyne and azido groups. Our results demonstrate that azido substitution at 3'-OH of nicotinamide riboside enables enzymatic synthesis of an NAD+ analogue with high efficiency and yields. Notably, the generated 3'-azido NAD+ exhibits unexpected high activity and specificity for protein PARylation catalyzed by human poly-ADP-ribose polymerase 1 (PARP1) and PARP2. And its derived poly-ADP-ribose polymers show increased resistance to human poly(ADP-ribose) glycohydrolase-mediated degradation. These unique properties lead to enhanced labeling of protein PARylation by 3'-azido NAD+ in the cellular contexts and facilitate direct visualization and labeling of mitochondrial protein PARylation. The 3'-azido NAD+ provides an important tool for studying cellular PARylation.
Sujet(s)
NAD/métabolisme , ADP ribose transferases/métabolisme , Chromatographie en phase liquide à haute performance , Cellules HeLa , Humains , Spectroscopie par résonance magnétique , Modèles biologiques , Nicotinamide nucleotide adenylyltransferase/métabolisme , Phosphotransferases (Alcohol Group Acceptor)/métabolisme , Poly (ADP-Ribose) polymerase-1/métabolisme , Poly(ADP-ribosylation) , Poly(ADP-ribose) polymerases/métabolisme , Protéines proto-oncogènes/métabolisme , Sirtuine-2/métabolismeRÉSUMÉ
The development of new therapies to treat methicillin-resistant Staphylococcus aureus (MRSA) is needed to counteract the significant threat that MRSA presents to human health. Novel inhibitors of DNA gyrase and topoisomerase IV (TopoIV) constitute one highly promising approach, but continued optimization is required to realize the full potential of this class of antibiotics. Herein, we report further studies on a series of dioxane-linked derivatives, demonstrating improved antistaphylococcal activity and reduced hERG inhibition. A subseries of analogues also possesses enhanced inhibition of the secondary target, TopoIV.